Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients
07. November 2017 12:22 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Biodesix® chief technology officer, Dr. Heinrich Roder, will give an oral presentation discussing a proprietary test development methodology that...
Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry
01. November 2017 12:12 ET
|
Biodesix, Inc.
BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Biodesix® presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data...
Biodesix To Present Data at SITC Annual Meeting
25. Oktober 2017 10:00 ET
|
Biodesix, Inc.
BOULDER, Colo., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Biodesix will conduct an oral presentation on immunotherapy biomarkers in addition to presenting data from two separate studies at the SITC 2017...
Introducing The Society For Advanced Bronchoscopy
28. September 2017 13:42 ET
|
Biodesix, Inc.; The Society for Advanced Bronchoscopy
TAMPA, Fla., Sept. 28, 2017 (GLOBE NEWSWIRE) -- The Society for Advanced Bronchoscopy announced its inception and plans for its first annual meeting today, citing the need to “promote and support...
Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test
20. September 2017 11:17 ET
|
Biodesix, Inc.
BOULDER, Colo., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Findings published in the peer-reviewed journal Managed Care showed that prognostic information provided by the Biodesix® VeriStrat test can...
Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer
15. September 2017 11:55 ET
|
Biodesix, Inc.
BOULDER, Colo., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Interim analysis of a new study examining the impact of VeriStrat testing on treatment decisions in patients with non-small cell lung cancer...
Biodesix Presents Cell-free DNA Process Optimization for Liquid Biopsy Test
08. August 2017 13:17 ET
|
Biodesix, Inc.
BOULDER, Colo., Aug. 08, 2017 (GLOBE NEWSWIRE) -- In two separate talks, Biodesix scientists presented information on further development and improvement of laboratory processes used for the...
Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy
10. Juli 2017 13:09 ET
|
Biodesix, Inc.
BOULDER, Colo., July 10, 2017 (GLOBE NEWSWIRE) -- Clinical findings published in the peer reviewed journal Lung Cancer show that the Biodesix® VeriStrat test is prognostic for outcomes in patients...
Biodesix® and Positive Bioscience Announce Partnership to Bring Cancer Tests to India
12. Juni 2017 12:37 ET
|
Biodesix, Inc.
BOULDER, Colo., June 12, 2017 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Boulder, CO, USA) and Positive Bioscience (Mumbai, India) announced today that they have entered into an agreement where Positive...
New Study Shows Advanced Diagnostic Tests, Including the VeriStrat® Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients
22. Mai 2017 13:31 ET
|
Biodesix, Inc.
BOULDER, Colo., May 22, 2017 (GLOBE NEWSWIRE) -- Today, Biodesix®, Inc. will present the results of a new study demonstrating that VeriStrat testing and other tools can help physicians improve...